Drugs /

ct041

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for ct041

Ct041 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ct041, 1 is phase 1 (1 open).

CLDN18 Expression is the most frequent biomarker inclusion criterion for ct041 clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and pancreatic adenocarcinoma are the most common diseases being investigated in ct041 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ct041
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ct041 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous anti-claudin18.2 chimeric antigen receptor t-cell therapy
Drug Target(s) [2]:
CLDN18

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.